GSK's Arexvy excels in two trials for at-risk patients age 18-49
1 day ago · Preliminary results from two trials showed that GSK’s respiratory syncytial virus (RSV) vaccine Arexvy has potential in younger adults with certain risk factors, potentially positioning the...
New data for AREXVY, GSK’s respiratory syncytial virus vaccine, …
1 day ago · The vaccine is currently approved for active immunization for the prevention of RSV-LRTD caused by RSV in adults aged 60 and older in over 50 countries, and in adults aged 50-59 at increased risk in a number of countries including the US and in Europe*.
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine…
1 day ago · The vaccine is currently approved for active immunization for the prevention of RSV-LRTD caused by RSV in adults aged 60 and older in over 50 countries, and in adults aged 50-59 at...
Arexvy Looks Promising for RSV Protection in Younger At-Risk …
21 hours ago · Arexvy is currently approved for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older, and those 50 to 59...
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK ...
20 hours ago · The vaccine is currently approved for active immunization to prevent RSV-LRTD in adults aged 60 and older and in adults aged 50-59 at increased risk. There are currently no RSV vaccines...
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the...
Real-World Study Confirms RSV Vaccine's, Arexvy and Abrysvo, …
FRIDAY, Oct. 18, 2024 -- A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization.
GSK Announces New Positive Data For RSV Vaccine, Arexvy In …
1 day ago · GSK plc (GSK.L) Thursday announced positive preliminary data from two studies evaluating its respiratory syncytial virus vaccine (RSV), Arexvy in adults aged 18-49 who are at increased risk for lower respiratory tract disease (LRTD) caused by RSV due to certain underlying medical conditions and in adults who are immunocompromised.
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine…
1 day ago · The vaccine is currently approved for active immunization for the prevention of RSV-LRTD caused by RSV in adults aged 60 and older in over 50 countries, and in adults aged 50-59 at increased...
RSV Vaccine Guidance for Older Adults | RSV | CDC
Aug 30, 2024 · What to know. CDC recommends a single dose of any FDA-licensed RSV vaccine for all adults ages 75 and older and adults ages 60–74 at increased risk of severe RSV. Three RSV vaccines are currently available for adults ages 60 and older: GSK’s Arexvy, Moderna’s mResvia, and Pfizer’s Abrysvo. Eligible older adults may receive any of the ...